AURA Takes you to the home page
 

Aberdeen University Research Archive >
6 - All research >
All research >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2164/270

This item has been viewed 4 times in the last year. View Statistics

Files in This Item:

File Description SizeFormat
Grant2009.pdf368.67 kBAdobe PDFView/Open
Title: Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease : UK collaborative randomised trial
Authors: Grant, Adrian Maxwell
Wileman, Samantha M
Ramsay, Craig R
Mowat, N Ashley
Krukowski, Zygmunt H
Heading, Robert C
Thursz, Mark R
Campbell, Marion Kay
REFLUX Trial Group
University of Aberdeen, School of Medicine & Dentistry, Division of Applied Health Sciences
Keywords: Fundoplication
Gastroesophageal Reflux
Quality of Life
Treatment Outcome
Issue Date: 10-Jan-2009
Publisher: BMJ
Citation: Grant, A.M., Wileman, S.M., Ramsay, C.R., Mowat, N.A., Krukowski, Z.H., Heading, R.C., Thurz, M.R., Campbell, M.K., and REFLUX Trial Group. (2009). Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease : UK collaborative randomised trial. BMJ, 337(a2664), pp. 81-84.
Abstract: ABSTRACT Objective To determine the relative benefits and risks of laparoscopic fundoplication surgery as an alternative to long term drug treatment for chronic gastro-oesophageal reflux disease (GORD). Design Multicentre, pragmatic randomised trial (with parallel preference groups). Setting 21 hospitals in the United Kingdom. Participants 357 randomised participants (178 surgical,179 medical) and 453 preference participants (261, 192); mean age 46; 66% men. All participants had documented evidence of GORD and symptoms for >12 months. Intervention The type of laparoscopic fundoplication used was left to the discretion of the surgeon. Those allocated to medical treatment had their treatment reviewed and adjusted as necessary by a local gastroenterologist, and subsequent clinical management was at the discretion of the clinician responsible for care. Main outcome measures The disease specific REFLUX quality of life score (primary outcome), SF-36, EQ-5D, and medication use, measured at time points equivalent to three and 12 months after surgery, and surgical complications. Main results Randomised participants had received drugs for GORD for median of 32 months before trial entry. Baseline REFLUX scores were 63.6 (SD 24.1) and 66.8 (SD 24.5) in the surgical and medical randomised groups, respectively. Of those randomised to surgery, 111 (62%) actually had total or partial fundoplication. Surgical complications were uncommon with a conversion rate of 0.6% and no mortality. By 12 months, 38% (59/154) randomised to surgery (14% (14/104) among those who had fundoplication) were taking reflux medication versus 90% (147/164) randomised medical management. The REFLUX score favoured the randomised surgical group (14.0, 95% confidence interval 9.6 to 18.4; P<0.001). Differences of a third to half of 1 SD in other health status measures also favoured the randomised surgical group. Baseline scores in the preference for surgery group were the worst; by 12 months these were better than in the preference for medical treatment group. Conclusion At least up to 12 months after surgery, laparoscopic fundoplication significantly increased measures of health status in patients with GORD. Trial registration ISRCTN15517081
URI: http://hdl.handle.net/2164/270
DOI: http://dx.doi.org/10.1136/bmj.a2664
ISSN: 0959-8138
Appears in Collections:Applied Health Sciences research
All research

SFX Query

Items in AURA are protected by copyright, with all rights reserved, unless otherwise indicated.

 


The University of Aberdeen
King's College
Aberdeen
AB24 3FX
Tel: +44 (0)1224-272000